Form 4 Filing for GeneDx Holdings Corp.

Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp., reported several transactions on April 29, 2026. Stueland acquired 3,874 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) with no cost, increasing her post-transaction shares to 95,388. Subsequently, she disposed of 2,154 shares at $65.20 per share and 18 shares at $64.12 per share, resulting in 93,216 shares remaining. These sales were to cover tax withholding obligations related to the vesting of RSUs, as indicated by footnote F2, and were not discretionary. Following these transactions, Stueland beneficially owns 93,216 shares of Class A Common Stock, along with RSUs and options for additional shares. The RSUs vest over time, with the last tranche vesting on April 29, 2026, as detailed in footnote F4.